CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on the drug DZNep, which shows promise in treating SARS-CoV-2 infections by inhibiting virus growth, enhancing innate immunity, and promoting tissue regeneration. It aims to advance from preclinical studies to clinical trials.
Our IP secured drug DZNep is effective in treating SARS-CoV-2 infections in preclinical disease models and uniquely suppresses virus growth, triggers the innate immunity and facilitates tissue regeneration.
The ERC-PoC will enable the transition from preclinical to clinical research.
TECHNISCHE UNIVERSITAET MUENCHEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
